Recombinant multi-species BCL2L2/BCL-W protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis

Genemedi produces recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine BCL2L2/BCL-W protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.
This gene encodes a member of the BCL-2 protein family. The proteins of this family form hetero- or homodimers and act as anti- and pro-apoptotic regulators. Expression of this gene in cells has been shown to contribute to reduced cell apoptosis under cytotoxic conditions. Studies of the related gene in mice indicated a role in the survival of NGF- and BDNF-dependent neurons. Mutation and knockout studies of the mouse gene demonstrated an essential role in adult spermatogenesis. Alternative splicing results in multiple transcript variants. Read-through transcription also exists between this gene and the neighboring downstream PABPN1 (poly(A) binding protein, nuclear 1) gene. [provided by RefSeq, Dec 2010]
The Alternative Names of target: Apoptosis regulator Bcl-W,BCL-W,BCL-WEL,BCL-WS,BCL2-L-2,BCL2L2,BCLW,Bcl-2-like protein 2,Bcl-w,Bcl2-L-2,Bcl2l2,Bclw,Gtrgal2,Gtrosa41,PPP1R51,RELA,bclw,c98

Target products collectionGo to BCL2L2/BCL-W products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No. Product Name Species Reactivity
GM-Tg-hg-IP0051-Ag-1/ GM-Tg-hg-IP0051-Ag-2 Human BCL2L2/BCL-W protein Human
GM-Tg-rg-IP0051-Ag-1/ GM-Tg-rg-IP0051-Ag-2 Rat BCL2L2/BCL-W protein Rat
GM-Tg-mg-IP0051-Ag-1/ GM-Tg-mg-IP0051-Ag-2 Mouse BCL2L2/BCL-W protein Mouse
GM-Tg-cynog-IP0051-Ag-1/ GM-Tg-cynog-IP0051-Ag-2 Cynomolgus/Rhesus macaque BCL2L2/BCL-W protein Cynomolgus/ Rhesus macaque
GM-Tg-felg-IP0051-Ag-1/ GM-Tg-felg-IP0051-Ag-2 Feline BCL2L2/BCL-W protein Feline
GM-Tg-cang-IP0051-Ag-1/ GM-Tg-cang-IP0051-Ag-2 Canine BCL2L2/BCL-W protein Canine
GM-Tg-bovg-IP0051-Ag-1/ GM-Tg-bovg-IP0051-Ag-2 Bovine BCL2L2/BCL-W protein Bovine
GM-Tg-equg-IP0051-Ag-1/ GM-Tg-equg-IP0051-Ag-2 Equine BCL2L2/BCL-W protein Equine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No. GM-Tg-hg-IP0051-Ag-1/ GM-Tg-hg-IP0051-Ag-2; GM-Tg-rg-IP0051-Ag-1/ GM-Tg-rg-IP0051-Ag-2;
GM-Tg-mg-IP0051-Ag-1/ GM-Tg-mg-IP0051-Ag-2; GM-Tg-cynog-IP0051-Ag-1/ GM-Tg-cynog-IP0051-Ag-2;
GM-Tg-felg-IP0051-Ag-1/ GM-Tg-felg-IP0051-Ag-2; GM-Tg-cang-IP0051-Ag-1/ GM-Tg-cang-IP0051-Ag-2;
GM-Tg-bovg-IP0051-Ag-1/ GM-Tg-bovg-IP0051-Ag-2; GM-Tg-equg-IP0051-Ag-1/ GM-Tg-equg-IP0051-Ag-2
Products Name BCL2L2/BCL-W protein
Species Human, Cynomolgus/ Rhesus macaque, rat, mouse, Feline, Canine, Bovine, Equine
Target Name BCL2L2/BCL-W
Protein Sub-location Introcelluar Protein
Isotypes Recombinant protein
Expression platform Mammalian cell
Bioactivity validation Affintiy&bioactivity validated by ELISA, cell culture validated.
Tag His
Products description Recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine BCL2L2/BCL-W protein was expressed in mammalian cell expression system and is expressed with 6 HIS tag at the C-terminus for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Purity Purity: ≥95% (SDS-PAGE)
Application In vitro study, in vivo study, benchmark, positive control for the diagnosis. Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference






    About Gmab

    GDU
    GDU

    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.